ARPP19 and acute myeloid leukemia: The prevalent role for PP2A inhibition in AML [10] and in other cancer types [9,27] provides a strong scientific rationale for the clinical association between low ARPP19 expression and a lower risk for AML relapse newly discovered in this study.